Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone

Praveen Ballabh, M. Simm, J. Kumari, C. Califano, Z. Aghai, G. Laborada, C. Sison, Susanna Cunningham-Rundles

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The first objective of this study was to evaluate longitudinal changes in respiratory burst activity in circulating neutrophils and monocytes in infants of less than 30 weeks of gestation with respiratory distress syndrome (RDS), and to examine differences in neonates who subsequently developed bronchopulmonary dysplasia (BPD) compared with those neonates who did not. The second objective was to investigate the effects of dexamethasone on respiratory burst activity in neutrophils and monocytes. We measured burst activity on neutrophils and monocytes in fresh heparinized blood in response to E. coli, N-formyl-met-leu-phe (fMLP), and phorbol 12-myristate 13-acetate stimulation on days 3, 7, 14, and 21 of life, before and 2-3 days after initiating a 6-day course of dexamethasone treatment. Infants with RDS participating in the study were followed until discharge, and were classified as non-BPD and either 1) BPD d28, reflecting their oxygen requirement at day of life 28, or 2) BPD 36 weeks, reflecting oxygen dependence at 36 weeks' corrected gestational age. The diagnosis of BPD was supported by radiological changes of BPD. The percentage of activated neutrophils producing a respiratory burst increased in all premature infants with increasing postnatal days during the first 28 days of life, when the physiological stimulus E. coli was used as an activator (P < 0.02). There was no significant difference in respiratory burst activity measured either as percent activation or as mean fluorescence intensity between non-BPD and BPD infants after adjusting for the difference in weight and gestational age between the two groups. The treatment of premature infants with dexamethasone was associated with decreased activation of neutrophils (P < 0.005) when E. coli was used as a stimulus. In conclusion, a significant increase in neutrophil respiratory burst activity occurs during the first month of life in very low birth weight infants. Greater pulmonary damage in BPD cannot be attributed to reduced burst activity in either neutrophils or monocytes. Dexamethasone treatment was associated with decreased neutrophil respiratory burst activity.

Original languageEnglish (US)
Pages (from-to)392-399
Number of pages8
JournalPediatric Pulmonology
Volume35
Issue number5
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Bronchopulmonary Dysplasia
Respiratory Burst
Dexamethasone
Neutrophils
Monocytes
Escherichia coli
Premature Infants
Gestational Age
Newborn Infant
Oxygen
Newborn Respiratory Distress Syndrome
Neutrophil Activation
Very Low Birth Weight Infant
Acetates
Therapeutics
Fluorescence
Weights and Measures
Pregnancy
Lung

Keywords

  • Bronchopulmonary dysplasia
  • Dexamethasone
  • Neonate
  • Respiratory burst activity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Ballabh, P., Simm, M., Kumari, J., Califano, C., Aghai, Z., Laborada, G., ... Cunningham-Rundles, S. (2003). Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone. Pediatric Pulmonology, 35(5), 392-399. https://doi.org/10.1002/ppul.10279

Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone. / Ballabh, Praveen; Simm, M.; Kumari, J.; Califano, C.; Aghai, Z.; Laborada, G.; Sison, C.; Cunningham-Rundles, Susanna.

In: Pediatric Pulmonology, Vol. 35, No. 5, 01.05.2003, p. 392-399.

Research output: Contribution to journalArticle

Ballabh, P, Simm, M, Kumari, J, Califano, C, Aghai, Z, Laborada, G, Sison, C & Cunningham-Rundles, S 2003, 'Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone', Pediatric Pulmonology, vol. 35, no. 5, pp. 392-399. https://doi.org/10.1002/ppul.10279
Ballabh, Praveen ; Simm, M. ; Kumari, J. ; Califano, C. ; Aghai, Z. ; Laborada, G. ; Sison, C. ; Cunningham-Rundles, Susanna. / Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone. In: Pediatric Pulmonology. 2003 ; Vol. 35, No. 5. pp. 392-399.
@article{a0acdff5302348e1bf5370b6afcc4243,
title = "Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone",
abstract = "The first objective of this study was to evaluate longitudinal changes in respiratory burst activity in circulating neutrophils and monocytes in infants of less than 30 weeks of gestation with respiratory distress syndrome (RDS), and to examine differences in neonates who subsequently developed bronchopulmonary dysplasia (BPD) compared with those neonates who did not. The second objective was to investigate the effects of dexamethasone on respiratory burst activity in neutrophils and monocytes. We measured burst activity on neutrophils and monocytes in fresh heparinized blood in response to E. coli, N-formyl-met-leu-phe (fMLP), and phorbol 12-myristate 13-acetate stimulation on days 3, 7, 14, and 21 of life, before and 2-3 days after initiating a 6-day course of dexamethasone treatment. Infants with RDS participating in the study were followed until discharge, and were classified as non-BPD and either 1) BPD d28, reflecting their oxygen requirement at day of life 28, or 2) BPD 36 weeks, reflecting oxygen dependence at 36 weeks' corrected gestational age. The diagnosis of BPD was supported by radiological changes of BPD. The percentage of activated neutrophils producing a respiratory burst increased in all premature infants with increasing postnatal days during the first 28 days of life, when the physiological stimulus E. coli was used as an activator (P < 0.02). There was no significant difference in respiratory burst activity measured either as percent activation or as mean fluorescence intensity between non-BPD and BPD infants after adjusting for the difference in weight and gestational age between the two groups. The treatment of premature infants with dexamethasone was associated with decreased activation of neutrophils (P < 0.005) when E. coli was used as a stimulus. In conclusion, a significant increase in neutrophil respiratory burst activity occurs during the first month of life in very low birth weight infants. Greater pulmonary damage in BPD cannot be attributed to reduced burst activity in either neutrophils or monocytes. Dexamethasone treatment was associated with decreased neutrophil respiratory burst activity.",
keywords = "Bronchopulmonary dysplasia, Dexamethasone, Neonate, Respiratory burst activity",
author = "Praveen Ballabh and M. Simm and J. Kumari and C. Califano and Z. Aghai and G. Laborada and C. Sison and Susanna Cunningham-Rundles",
year = "2003",
month = "5",
day = "1",
doi = "10.1002/ppul.10279",
language = "English (US)",
volume = "35",
pages = "392--399",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone

AU - Ballabh, Praveen

AU - Simm, M.

AU - Kumari, J.

AU - Califano, C.

AU - Aghai, Z.

AU - Laborada, G.

AU - Sison, C.

AU - Cunningham-Rundles, Susanna

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The first objective of this study was to evaluate longitudinal changes in respiratory burst activity in circulating neutrophils and monocytes in infants of less than 30 weeks of gestation with respiratory distress syndrome (RDS), and to examine differences in neonates who subsequently developed bronchopulmonary dysplasia (BPD) compared with those neonates who did not. The second objective was to investigate the effects of dexamethasone on respiratory burst activity in neutrophils and monocytes. We measured burst activity on neutrophils and monocytes in fresh heparinized blood in response to E. coli, N-formyl-met-leu-phe (fMLP), and phorbol 12-myristate 13-acetate stimulation on days 3, 7, 14, and 21 of life, before and 2-3 days after initiating a 6-day course of dexamethasone treatment. Infants with RDS participating in the study were followed until discharge, and were classified as non-BPD and either 1) BPD d28, reflecting their oxygen requirement at day of life 28, or 2) BPD 36 weeks, reflecting oxygen dependence at 36 weeks' corrected gestational age. The diagnosis of BPD was supported by radiological changes of BPD. The percentage of activated neutrophils producing a respiratory burst increased in all premature infants with increasing postnatal days during the first 28 days of life, when the physiological stimulus E. coli was used as an activator (P < 0.02). There was no significant difference in respiratory burst activity measured either as percent activation or as mean fluorescence intensity between non-BPD and BPD infants after adjusting for the difference in weight and gestational age between the two groups. The treatment of premature infants with dexamethasone was associated with decreased activation of neutrophils (P < 0.005) when E. coli was used as a stimulus. In conclusion, a significant increase in neutrophil respiratory burst activity occurs during the first month of life in very low birth weight infants. Greater pulmonary damage in BPD cannot be attributed to reduced burst activity in either neutrophils or monocytes. Dexamethasone treatment was associated with decreased neutrophil respiratory burst activity.

AB - The first objective of this study was to evaluate longitudinal changes in respiratory burst activity in circulating neutrophils and monocytes in infants of less than 30 weeks of gestation with respiratory distress syndrome (RDS), and to examine differences in neonates who subsequently developed bronchopulmonary dysplasia (BPD) compared with those neonates who did not. The second objective was to investigate the effects of dexamethasone on respiratory burst activity in neutrophils and monocytes. We measured burst activity on neutrophils and monocytes in fresh heparinized blood in response to E. coli, N-formyl-met-leu-phe (fMLP), and phorbol 12-myristate 13-acetate stimulation on days 3, 7, 14, and 21 of life, before and 2-3 days after initiating a 6-day course of dexamethasone treatment. Infants with RDS participating in the study were followed until discharge, and were classified as non-BPD and either 1) BPD d28, reflecting their oxygen requirement at day of life 28, or 2) BPD 36 weeks, reflecting oxygen dependence at 36 weeks' corrected gestational age. The diagnosis of BPD was supported by radiological changes of BPD. The percentage of activated neutrophils producing a respiratory burst increased in all premature infants with increasing postnatal days during the first 28 days of life, when the physiological stimulus E. coli was used as an activator (P < 0.02). There was no significant difference in respiratory burst activity measured either as percent activation or as mean fluorescence intensity between non-BPD and BPD infants after adjusting for the difference in weight and gestational age between the two groups. The treatment of premature infants with dexamethasone was associated with decreased activation of neutrophils (P < 0.005) when E. coli was used as a stimulus. In conclusion, a significant increase in neutrophil respiratory burst activity occurs during the first month of life in very low birth weight infants. Greater pulmonary damage in BPD cannot be attributed to reduced burst activity in either neutrophils or monocytes. Dexamethasone treatment was associated with decreased neutrophil respiratory burst activity.

KW - Bronchopulmonary dysplasia

KW - Dexamethasone

KW - Neonate

KW - Respiratory burst activity

UR - http://www.scopus.com/inward/record.url?scp=0037730275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037730275&partnerID=8YFLogxK

U2 - 10.1002/ppul.10279

DO - 10.1002/ppul.10279

M3 - Article

VL - 35

SP - 392

EP - 399

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 5

ER -